Transoma brings in $5M for heart diagnostics
Transoma, maker of cardiovascular monitoring and diagnostic products, landed $5 million in fourth-round funding from United Therapeutics, Affinity Capital Management, Canaan Partners, Cross Creek Capital and Polaris Venture Partners, reports VentureWire. The money comes after the company withdrew its filing to go public earlier this year.
Based in St. Paul, Minn., the biotech company hoped to bring in $67.2 million on 4.2 million shares, but decided against going public due to unfavorable market conditions. Before it filed in November, it had raised $37 million in VC backing.
Next Story: PlantSense launches EasyBloom plant monitoring sensors
Previous Story: Xanodyne newest pharm co. to cancel IPO
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
